Elevance Health Holds Annual Shareholders Meeting

An update from Elevance Health ( (ELV) ) is now available.

On May 14, 2025, Elevance Health, Inc. held its Annual Meeting of Shareholders where several key decisions were made. The election of directors saw Susan D. DeVore, Bahija Jallal, and Ryan M. Schneider elected for three-year terms. The advisory vote on executive compensation was approved, and the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2025 was ratified. However, a shareholder proposal requesting a report on Diversity, Equity, and Inclusion efforts was not approved.

The most recent analyst rating on (ELV) stock is a Buy with a $600.00 price target. To see the full list of analyst forecasts on Elevance Health stock, see the ELV Stock Forecast page.

Spark’s Take on ELV Stock

According to Spark, TipRanks’ AI Analyst, ELV is a Outperform.

Elevance Health’s overall score of 71 reflects a strong financial foundation with consistent revenue growth and solid profitability, though offset by technical weaknesses and challenges in the Medicaid segment. Valuation is fair, but not compelling enough alone to drive a strong buy recommendation. The earnings call provided positive strategic updates, yet acknowledged ongoing cost pressures. Overall, this positions Elevance Health as a stable investment with areas for improvement, especially in technical momentum and cost management.

To see Spark’s full report on ELV stock, click here.

More about Elevance Health

Elevance Health, Inc. operates in the healthcare industry, focusing on providing health insurance and related services. The company is known for its comprehensive healthcare plans and services, catering to a wide range of market segments.

Average Trading Volume: 1,709,323

Technical Sentiment Signal: Sell

Current Market Cap: $94.14B

See more data about ELV stock on TipRanks’ Stock Analysis page.